MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.,Cell Metabolism

当前位置： X-MOL 学术 › Cell Metab. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.
Cell Metabolism ( IF 29.0 ) Pub Date : 2017-Oct-03 , DOI: 10.1016/j.cmet.2017.09.009
Kyung-min Lee , Jennifer M. Giltnane , Justin M. Balko , Luis J. Schwarz , Angel L. Guerrero-Zotano , Katherine E. Hutchinson , Mellissa J. Nixon , Mónica V. Estrada , Violeta Sánchez , Melinda E. Sanders , Taekyu Lee , Henry Gómez , Ana Lluch , J. Alejandro Pérez-Fidalgo , Melissa Magdalene Wolf , Gabriela Andrejeva , Jeffrey C. Rathmell , Stephen W. Fesik , Carlos L. Arteaga

Most patients with advanced triple-negative breast cancer (TNBC) develop drug resistance. MYC and MCL1 are frequently co-amplified in drug-resistant TNBC after neoadjuvant chemotherapy. Herein, we demonstrate that MYC and MCL1 cooperate in the maintenance of chemotherapy-resistant cancer stem cells (CSCs) in TNBC. MYC and MCL1 increased mitochondrial oxidative phosphorylation (mtOXPHOS) and the generation of reactive oxygen species (ROS), processes involved in maintenance of CSCs. A mutant of MCL1 that cannot localize in mitochondria reduced mtOXPHOS, ROS levels, and drug-resistant CSCs without affecting the anti-apoptotic function of MCL1. Increased levels of ROS, a by-product of activated mtOXPHOS, led to the accumulation of HIF-1α. Pharmacological inhibition of HIF-1α attenuated CSC enrichment and tumor initiation in vivo. These data suggest that (1) MYC and MCL1 confer resistance to chemotherapy by expanding CSCs via mtOXPHOS and (2) targeting mitochondrial respiration and HIF-1α may reverse chemotherapy resistance in TNBC.

更新日期：2017-10-03

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>